Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Some bladder primary tumors and some bladder and melanoma tumor cell lines contain mutations in both P16 and P53 at frequencies that suggest that p53 and p16 function in different pathways, each of which is important in suppressing malignant transformation. 7747814 1995
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE We conclude that disruption of the CDKN2 gene is not required for malignant transformation of human neuroblastomas. 7743501 1995
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Also suggested is that p16 has no role in the specific malignant transformation step from immortal premalignant lesions during the carcinogenesis of HPV-initiated cervical cancers. 9166931 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation phenotype BEFREE Results of this study suggest that two different genetic alterations, the inactivation of the p16 gene and genetic instability, play roles in the malignant transformation of carcinoma in pleomorphic adenoma. 9917133 1998
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression phenotype BEFREE Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. 10595918 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Tumor-suppressor gene p16 is an important negative cell-cycle regulator whose functional loss may significantly contribute to malignant transformation and progression. 10854145 2000
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Selective methylation was found in 19% for p16(INK4a), 36% for p15(INK4b), and 6.5% for both genes in MGUS, and frequencies were similar in MM suggesting that methylation of these genes is an early event, not associated with transition from MGUS to MM. p15(INK4b) and p16(INK4a) gene methylation might contribute to immortalization of plasma cells rather than malignant transformation in the natural history of MM. 11418489 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression phenotype BEFREE Since in our series just one out of eight anaplastic cases showed negative immunostaining and CDKN2A HD, p16/CDKN2A inactivation may not play an important role in the malignant transformation of ependymomas. 11763427 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation phenotype BEFREE This study evaluated INK4a/ARF locus alterations in 26 patients (28 samples) deemed to be at increased risk for malignant transformation to squamous cell carcinoma due to the diagnosis of severe oral epithelial dysplasia. 12234999 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression phenotype BEFREE We conclude (1) that p16(INK4a) epigenetic inactivation most likely represents an early event, insufficient for malignant transformation, that may occur in clinically benign lesions such as LS; (2) that lack of pRb was only detected in fewer than one quarter of the carcinomas and could be considered a late secondary event; and (3) that cyclin-D1, which was overexpressed in VC and VIN, could contribute to the malignant transformation in association with p16 hypermethylation. 12454817 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation phenotype BEFREE The observation that alterations of p14(ARF) and p16(INK4a), and also p53 mutations, occurred exclusively in the epithelial and transitional components of pleomorphic adenoma supports the theory that these areas are prone to malignant transformation to carcinoma in adenoma. 12375265 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression phenotype BEFREE In this report, we analyzed the methylation status of hMLH1 and p16 and the protein expression of PTEN and hMLH1 in 46 cases of endometriosis stages III and IV to better define the possible involvement of these genes in the malignant transformation of endometriosis. 12402310 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE These results suggest that loss of p16(INK4A) gene on 9p may contribute to the progression and/or malignant transformation of GISTs. 15181453 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 PosttranslationalModification phenotype BEFREE The aim of this study is to investigate the relationship between p16 methylation and malignant transformation of human gastric dysplasia (DYS) based on follow-up endoscopic screening in a high-risk population. 15297411 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 PosttranslationalModification phenotype BEFREE Methylation of the p16 gene may contribute to the malignant transformation of gastric precursor lesions. 15064707 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. 15930270 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Methylation of p16 and Ras association domain family protein 1a during colorectal malignant transformation. 16687485 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation phenotype BEFREE We also examined deletion of cyclin-dependent kinase inhibitor 4 (INK4) genes and mutation of p53 gene in combination with changes in the HTLV-I genome in acute type ATL to test whether host genetic changes promoted the malignant transformation of ATL cells that carry putative CTL escape mutations. 16052518 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE It has been suggested that the up-regulation of the tumour suppressor p16 gene and induction of senescence protect the phenotype of psoriatic involved skin from malignant transformation. 16552541 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Inactivation of the p16(INK4a)/Rb pathway may allow continuous cell division and critical telomere shortening, which induce genome instability, finally leading to malignant transformation. 17428253 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression phenotype BEFREE Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. 17292825 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE Deletions of RB1 and/or CDKN2A were observed in 71% of LGGs and in 90% of tumors after MT. 17308273 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker phenotype BEFREE JunB is an essential upstream regulator of p16 and contributes to maintain cell senescence that blocks malignant transformation of TAC. 18628455 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 PosttranslationalModification phenotype BEFREE We thus conclude that methylation of the p16 gene promoter shows promise as a predictor for malignant transformation (Fisher's exact, P = 0.002) in a subset of patients. 18708411 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression phenotype BEFREE HMEC that express p16INK4A and vHMEC that do not, were transduced with constitutively active Ha-rasV12 and subsequently exposed to serum to determine whether signals from the cellular microenvironment could cooperate with ras to promote the malignant transformation of vHMEC. 19995452 2009